24 April 2021, Expert meeting. Professors Grigoriadis and Boyko gave an update on the role of the microbiome in multiple sclerosis. They discuss the function of the microbiome, its importance in the health of the individual, and how its dysregulation is implicated in altered immune responses in MS. Consult here the slide deck.
The human microbiome consists of microbes that co-exist in the human body, usually in a symbiotic or mutually beneficial manner. This host-microbiome interaction is highly complex and can become dysregulated, as has been observed in multiple sclerosis (MS) patients. In this presentation, Professors Grigoriadis and Boyko discuss the function of the microbiome, its importance in the health of the individual, and how its dysregulation is implicated in altered immune responses in MS. They also discuss how some currently approved disease-modifying therapies may alter the microbiome, and consider future directions for research on the role of the microbiome in MS.
Nikolaos Grigoriadis graduated from the Faculty of Medicine of the Aristotle University of Thessaloniki. He did his PhD thesis and residency in Neurology in the same institution. He has been specialized in clinical and experimental Neuroimmunology and CNS immunopathology in a number of research centers and institutions abroad. He is now Professor of Neurology at the Aristotle University of Thessaloniki and Head of the of the B’ Dept of Neurology, AHEPA University Hospital, the MS Centre and the Laboratory of Experimental Neurology and Neuroimmunology (www.neuroimmunology.gr). Professor Grigoriadis is member of various international scientific committees such as the European School of Neuroimmunology, ParadigMS, the subcommittee of ENS for Multiple Sclerosis, the ECTRIMS committee (until 2010), Co-founder and Secretary of the Hellenic Academy of Neuroimmunology (www.helani.gr). He is President of the Hellenic Neurological Society. He is Ad Hoc reviewer in more than 40 international scientific journals, co-Ordinator in more than 40 multicenter clinical trials for MS and principal investigator in collaborative research projects for experimental cell therapies in CNS autoimmune demyelination. His field of interests are: Neuroimmunology; Multiple sclerosis; experimental models of autoimmune diseases (EAE etc); neurodegeneration; immunomodulation; cell therapies. He has published more than 180 papers in peer reviewed journals. He has been awarded several times for his scientific work.
Alexey Boyko gained his MD and PhD from the Russian State Medical University, Moscow and has been Professor of the Department of Neurology and Neurosurgery at this university since 1997. He was the Chief Neurologist of the Department of Health Care of the Government of Moscow in 2001-2015. He works as the Director of the Moscow Multiple Sclerosis Centre and Director of the Institute of Clinical Neurology and Department of Neuroimmunology at the Federal Centre of Brain Research and Neurothechnologies. He was also elected as Honourable Professor of Kazan and Yaroslavl State Medical Universities. He is also a member of the Presidium of the AllRussian Society of Neurologists, Co-ordinator of the Medical Consulting Boards of Moscow and All-Russian MS Societies, President of RUCTRIMS, member of ECTRIMS Council, Member of the Board of the European Charcot Foundation (ECF). It 2017 he was elected as Honored Scientist of Russian Federation. Professor Boyko has published 17 books and more than 900 original publications, he is Co-editor of three medical journals, a member of Editorial Boards of 5 journals, including MSJ and MSRD. The main interest is epidemiology and genetic of MS, neuroimmunology, clinical trials in MS, he is a member of several Advisory Boards of ongoing and finished clinical trials.